businesspress24.com - Corcept Therapeutics to Announce First Quarter Financial Results and Corporate Update and Host Confe
 

Corcept Therapeutics to Announce First Quarter Financial Results and Corporate Update and Host Conference Call

ID: 1431557

(firmenpresse) - MENLO PARK, CA -- (Marketwired) -- 04/29/16 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 3, 2016. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

To participate, dial 1-888-771-4371 from the United States or 1-847-585-4405 internationally approximately 10 minutes before the start of the call. The passcode is 42398569.

A replay will be available through May 17, 2016 at 1-888-843-7419 from the United States and 1-630-652-3042 internationally. The passcode is 42398569.

Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Korlym, a first-generation cortisol modulator, is the company''s first FDA-approved medication. The company is conducting a Phase 1/2 trial of mifepristone for the treatment of TNBC and a Phase 1/2 trial of CORT125134 to treat a variety of solid-tumor cancers. It has a portfolio of other proprietary selective GR antagonists that modulate the effects of cortisol but not progesterone. Corcept owns extensive intellectual property covering the use of cortisol modulators, including mifepristone and CORT125134, in the treatment of a wide variety of metabolic, oncologic and psychiatric disorders. It also holds composition of matter patents for CORT125134 and its other selective cortisol modulators.



CONTACT:
Charles Robb
Chief Financial Officer
Corcept Therapeutics
650-688-8783



Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  SciVac Therapeutics Inc. Announces Reverse Stock Split
Japanese Patent Grants for IMP321 in Cancer
Bereitgestellt von Benutzer: Marketwired
Datum: 29.04.2016 - 06:30 Uhr
Sprache: Deutsch
News-ID 1431557
Anzahl Zeichen: 2674

contact information:
Contact person:
Town:

MENLO PARK, CA


Phone:

Kategorie:

Biotech


Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:


Diese Pressemitteilung wurde bisher 290 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Corcept Therapeutics to Announce First Quarter Financial Results and Corporate Update and Host Conference Call
"
steht unter der journalistisch-redaktionellen Verantwortung von

Corcept Therapeutics (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Corcept Therapeutics



 

Who is online

All members: 10 564
Register today: 1
Register yesterday: 0
Members online: 0
Guests online: 87


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.